Viking Stock Based Compensation from 2010 to 2024

VKTX Stock  USD 52.94  1.57  2.88%   
Viking Therapeutics Stock Based Compensation yearly trend continues to be fairly stable with very little volatility. Stock Based Compensation is likely to outpace its year average in 2024. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals
 
Stock Based Compensation  
First Reported
2014-09-30
Previous Quarter
7.1 M
Current Value
M
Quarterly Volatility
2.1 M
 
Yuan Drop
 
Covid
Check Viking Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Viking Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 277.4 K, Interest Expense of 83.6 K or Selling General Administrative of 38.9 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.29. Viking financial statements analysis is a perfect complement when working with Viking Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Viking Therapeutics Correlation against competitors.
For more information on how to buy Viking Stock please use our How to Invest in Viking Therapeutics guide.

Latest Viking Therapeutics' Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of Viking Therapeutics over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Viking Therapeutics' Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Viking Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Stock Based Compensation10 Years Trend
Slightly volatile
   Stock Based Compensation   
       Timeline  

Viking Stock Based Compensation Regression Statistics

Arithmetic Mean4,475,538
Geometric Mean102,774
Coefficient Of Variation129.27
Mean Deviation4,340,108
Median2,601,448
Standard Deviation5,785,522
Sample Variance33.5T
Range17.6M
R-Value0.86
Mean Square Error9.3T
R-Squared0.74
Significance0.000037
Slope1,113,961
Total Sum of Squares468.6T

Viking Stock Based Compensation History

202417.6 M
202316.8 M
20228.7 M
20216.1 M
20205.8 M
20193.7 M
20182.6 M

Other Fundumenentals of Viking Therapeutics

Viking Therapeutics Stock Based Compensation component correlations

-0.87-0.820.670.310.881.01.0-0.230.88-0.83-0.660.680.95-0.610.9-0.110.980.98-0.61
-0.870.96-0.87-0.51-0.79-0.89-0.880.15-0.650.740.59-0.62-0.760.71-0.840.1-0.82-0.820.71
-0.820.96-0.92-0.59-0.78-0.84-0.840.03-0.610.780.67-0.69-0.70.7-0.830.0-0.77-0.770.7
0.67-0.87-0.920.720.640.70.7-0.010.45-0.63-0.530.540.54-0.660.69-0.030.60.61-0.66
0.31-0.51-0.590.720.440.360.350.050.25-0.4-0.340.390.31-0.240.460.020.340.34-0.24
0.88-0.79-0.780.640.440.880.88-0.160.93-0.91-0.740.830.93-0.240.990.070.920.93-0.24
1.0-0.89-0.840.70.360.881.0-0.220.88-0.84-0.660.690.94-0.620.9-0.110.970.97-0.62
1.0-0.88-0.840.70.350.881.0-0.220.88-0.84-0.660.690.94-0.620.9-0.110.970.97-0.62
-0.230.150.03-0.010.05-0.16-0.22-0.22-0.22-0.16-0.460.4-0.290.01-0.260.83-0.28-0.280.01
0.88-0.65-0.610.450.250.930.880.88-0.22-0.88-0.70.750.94-0.180.910.00.920.93-0.18
-0.830.740.78-0.63-0.4-0.91-0.84-0.84-0.16-0.880.94-0.94-0.810.32-0.88-0.25-0.82-0.830.32
-0.660.590.67-0.53-0.34-0.74-0.66-0.66-0.46-0.70.94-0.95-0.620.27-0.68-0.45-0.64-0.640.27
0.68-0.62-0.690.540.390.830.690.690.40.75-0.94-0.950.7-0.190.770.520.70.7-0.19
0.95-0.76-0.70.540.310.930.940.94-0.290.94-0.81-0.620.7-0.350.93-0.110.990.99-0.35
-0.610.710.7-0.66-0.24-0.24-0.62-0.620.01-0.180.320.27-0.19-0.35-0.320.17-0.45-0.451.0
0.9-0.84-0.830.690.460.990.90.9-0.260.91-0.88-0.680.770.93-0.32-0.050.940.94-0.32
-0.110.10.0-0.030.020.07-0.11-0.110.830.0-0.25-0.450.52-0.110.17-0.05-0.12-0.120.17
0.98-0.82-0.770.60.340.920.970.97-0.280.92-0.82-0.640.70.99-0.450.94-0.121.0-0.45
0.98-0.82-0.770.610.340.930.970.97-0.280.93-0.83-0.640.70.99-0.450.94-0.121.0-0.45
-0.610.710.7-0.66-0.24-0.24-0.62-0.620.01-0.180.320.27-0.19-0.351.0-0.320.17-0.45-0.45
Click cells to compare fundamentals

About Viking Therapeutics Financial Statements

Viking Therapeutics investors use historical fundamental indicators, such as Viking Therapeutics' Stock Based Compensation, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Viking Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Stock Based Compensation16.8 M17.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Viking Stock Analysis

When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.